Opiant Pharmaceuticals Inc - Strategy, SWOT and Corporate Finance Report

Opiant Pharmaceuticals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Scope

  • Detailed information on Opiant Pharmaceuticals Inc required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Opiant Pharmaceuticals Inc in the form of a SWOT analysis
  • An in-depth view of the business model of Opiant Pharmaceuticals Inc including a breakdown and examination of key business segments
  • News about Opiant Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Opiant Pharmaceuticals Inc and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Opiant Pharmaceuticals Inc as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Opiant Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Shire Plc

Orexo AB

Insys Therapeutics Inc

Indivior Plc

H. Lundbeck AS

Cerecor Inc

Camurus AB

BioDelivery Sciences International Inc

BioCorRx Inc

Alkermes Plc

Shire Plc

Orexo AB

Insys Therapeutics Inc

Indivior Plc

H. Lundbeck AS

Cerecor Inc

Camurus AB

BioDelivery Sciences International Inc

BioCorRx Inc

Alkermes Plc

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Opiant Pharmaceuticals Inc ...

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Opiant Pharmaceuticals Inc - Key Facts 6

Opiant Pharmaceuticals Inc - Key Employees 7

Opiant Pharmaceuticals Inc - Key Employee Biographies 8

Opiant Pharmaceuticals Inc - Major Products and Services 9

Opiant Pharmaceuticals Inc - History 10

Opiant Pharmaceuticals Inc - Company Statement 12

Opiant Pharmaceuticals Inc - Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2 – Company Analysis 14

Company Overview 14

Opiant Pharmaceuticals Inc - Business Description 15

Opiant Pharmaceuticals Inc - Corporate Strategy 16

Opiant Pharmaceuticals Inc - SWOT Analysis 17

SWOT Analysis - Overview 17

Opiant Pharmaceuticals Inc - Strengths 17

Opiant Pharmaceuticals Inc - Weaknesses 18

Opiant Pharmaceuticals Inc - Opportunities 19

Opiant Pharmaceuticals Inc - Threats 20

Opiant Pharmaceuticals Inc - Key Competitors 21

Section 3 – Company Financial Ratios 22

Financial Ratios - Capital Market Ratios 22

Financial Ratios - Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios - Interim Ratios 26

Financial Ratios - Ratio Charts 27

Section 4 – Company’s Lifesciences Financial Deals and Alliances 28

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Opiant Pharmaceuticals Inc, Recent Deals Summary 30

Section 5 – Company’s Recent Developments 31

Sep 20, 2018: HHS sponsors development of intranasal form of long-acting opioid overdose drug 31

Sep 12, 2018: Consort to develop delivery device for opioid overdose drug 32

Sep 12, 2018: Consort to develop delivery device for opioid overdose drug 33

Sep 10, 2018: Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose[Newswire : Healthcare - GNW RSS] 34

Sep 10, 2018: Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose[Newswire : Healthcare - GNW RSS] 36

Sep 04, 2018: Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa[Newswire : Healthcare - GNW RSS] 38

Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 40

Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 42

Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 44

Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 46

Section 6 – Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

Disclaimer 52

List of Tables

List of Tables

Opiant Pharmaceuticals Inc, Key Facts 6

Opiant Pharmaceuticals Inc, Key Employees 7

Opiant Pharmaceuticals Inc, Key Employee Biographies 8

Opiant Pharmaceuticals Inc, ...

List of Tables

Opiant Pharmaceuticals Inc, Key Facts 6

Opiant Pharmaceuticals Inc, Key Employees 7

Opiant Pharmaceuticals Inc, Key Employee Biographies 8

Opiant Pharmaceuticals Inc, Major Products and Services 9

Opiant Pharmaceuticals Inc, History 10

Opiant Pharmaceuticals Inc, Subsidiaries 13

Opiant Pharmaceuticals Inc, Key Competitors 21

Opiant Pharmaceuticals Inc, Ratios based on current share price 22

Opiant Pharmaceuticals Inc, Annual Ratios 23

Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1) 24

Opiant Pharmaceuticals Inc, Interim Ratios 26

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Opiant Pharmaceuticals Inc, Recent Deals Summary 30

Currency Codes 48

Capital Market Ratios 48

Equity Ratios 49

Profitability Ratios 49

Cost Ratios 50

Liquidity Ratios 50

Leverage Ratios 51

Efficiency Ratios 51

List of Figures

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2013 - 2017) 25

Opiant Pharmaceuticals Inc, Ratio Charts 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals ...

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2013 - 2017) 25

Opiant Pharmaceuticals Inc, Ratio Charts 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports